Japanese encephalitis Japanese encephalitis vaccine Hematopoietic stem cell transplantation
Conditions
Interventions
inactivated vero cell culture-
derived JE vaccine (Beijing P3) 0.5 mL subcutaneous injection 3 doses [2 dose of primary series and 1 booster dose]
Experimental Drug
inactivated Vero cell culture-
derived JE vaccine (JEVAC)
Sponsors
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
No minimum to 25 Years
Inclusion criteria
Inclusion criteria: Patients who had finished their hematopoietic stem cell transplantation for more than 1 year
Exclusion criteria
Exclusion criteria: No immunosuppressive therapy at least 6 months before enrollment No evidence of acute or chronic graft versus host disease at the time of enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rate at 1 month after primary series of revaccination and 1 month after booster dose Antibody level against JE virus using plaque reduction neutralization test | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event after each dose of vaccine Observation and telephone call,Increment of JE specific T lymphocyte at 1 month after primary series of revaccination and 1 month after booster dose Number of JE specific T lymphocyte usinf interferon gamma releasing assay | — |
Countries
Thailand
Contacts
Public ContactSurapat Assawawiroonhakarn
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed